IL6R and pleural neoplasm: Further, addition of the IL-6Rα antagonist tocilizumab to cultures containing CFF completely abrogated tumor EMT, driving tumor cells to transition to epithelioid morphology (Figures 5C, D) and indicating that pleural tumor cells have the plasticity to revert from mesenchymal to epithelial states (MET).